<DOC>
	<DOCNO>NCT01831232</DOCNO>
	<brief_summary>This clinical trial study idarubicin , cytarabine , pravastatin sodium treat patient newly diagnose acute myeloid leukemia myelodysplastic syndrome . Drugs use chemotherapy , idarubicin cytarabine , work different way stop growth cancer cell , either kill cell stop dividing . Pravastatin sodium may stop growth cancer cell block enzymes need cell growth . Giving idarubicin cytarabine together pravastatin sodium may kill cancer cell .</brief_summary>
	<brief_title>Idarubicin , Cytarabine , Pravastatin Sodium Treating Patients With Acute Myeloid Leukemia Myelodysplastic Syndromes</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess rate achieve `` good complete response ( CR ) '' treat patient newly diagnose acute myeloid leukemia ( AML ) idarubicin , cytarabine pravastatin ( pravastatin sodium ) ( IAP ) . II . To determine toxicity ( death within 28 day start therapy = treatment related mortality `` TRM '' ) IAP newly-diagnosed AML . SECONDARY OBJECTIVES : I . To determine rate complete remission ( CR ) , remission incomplete blood count recovery ( CRi ) , partial remission ( PR ) , relapse-free survival overall survival . II . To identify biomarkers ( ie . change serum cholesterol ) associate clinical response . OUTLINE : Patients receive pravastatin sodium orally ( PO ) daily ( QD ) day 1-8 , idarubicin intravenously ( IV ) 10-15 minute day 4-6 , cytarabine IV continuously day 4-7 . Treatment repeat every 28-56 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year annually 3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis acute myeloid leukemia World Health Organization ( WHO ) 2008 criterion , include patient &gt; = 20 % blast bone marrow peripheral blood ( except acute promyelocytic leukemia ) , myelodysplastic syndrome refractory anemia excess blast ( RAEB ) 2 WHO classification advance myeloproliferative neoplasm &gt; = 10 % blast bone marrow peripheral blood , include chronic myelomonocytic leukemia ( CMML ) CMML2 WHO 2008 classification Untreated AML highrisk myelodysplastic syndrome ( MDS ) simplify TRM score = &lt; 9.2 Bilirubin &lt; 2.0 mg/ml Any creatinine value acceptable Any performance status eligible Life expectancy otherwise &gt; 1 year Patients exclude base cardiac history Females childbearing potential must negative serum pregnancy test within 2 week prior enrollment Patients must use effective contraceptive method study minimum 90 day study treatment Capable understanding investigational nature , potential risk benefit study , able provide valid inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>